These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1381 related items for PubMed ID: 19815292

  • 21. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 22. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration.
    Rezar-Dreindl S, Sacu S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, Weigert G, Schmidt-Erfurth U.
    Invest Ophthalmol Vis Sci; 2016 Aug 01; 57(10):4144-50. PubMed ID: 27537264
    [Abstract] [Full Text] [Related]

  • 23. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.
    Retina; 2011 May 01; 31(5):871-9. PubMed ID: 21358461
    [Abstract] [Full Text] [Related]

  • 24. Monitoring ocular drug therapy by analysis of aqueous samples.
    Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR.
    Ophthalmology; 2009 Nov 01; 116(11):2158-64. PubMed ID: 19700195
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY, Chan WM, Liu DT, Lam DS.
    Retina; 2009 Jun 01; 29(6):750-6. PubMed ID: 19357555
    [Abstract] [Full Text] [Related]

  • 29. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.
    Ahlers C, Golbaz I, Stock G, Fous A, Kolar S, Pruente C, Schmidt-Erfurth U.
    Ophthalmology; 2008 Aug 01; 115(8):e39-46. PubMed ID: 18675694
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function.
    Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U.
    Invest Ophthalmol Vis Sci; 2009 May 01; 50(5):2376-83. PubMed ID: 19136707
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May 01; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 34. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y, Nakamura Y, Yoneyama S, Mabuchi F, Gotoh T, Tateno Y, Sugiyama A, Kubota T, Iijima H.
    Ophthalmic Res; 2015 May 01; 53(1):2-7. PubMed ID: 25472810
    [Abstract] [Full Text] [Related]

  • 35. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B, Adewoyin T, Patel SK, Sivaprasad S.
    Br J Ophthalmol; 2011 Mar 01; 95(3):386-90. PubMed ID: 20693484
    [Abstract] [Full Text] [Related]

  • 36. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R.
    Am J Ophthalmol; 2009 Feb 01; 147(2):298-306. PubMed ID: 18929354
    [Abstract] [Full Text] [Related]

  • 37. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB.
    Retina; 2010 Oct 01; 30(9):1376-85. PubMed ID: 20683380
    [Abstract] [Full Text] [Related]

  • 38. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
    Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B, MARINA and ANCHOR Study Groups.
    Ophthalmology; 2011 Mar 01; 118(3):523-30. PubMed ID: 20920825
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 70.